By Editor , 1 October 2026
ICEYE, Nokia Partner on Sovereign Satellite Comms for 2028 Launch

Helsinki – October 01, 2026 -- ICEYE and Nokia have agreed to jointly develop secure, sovereign low Earth orbit (LEO) satellite communications systems for governments and defense customers, with the first satellites expected to launch in 2028.

By Editor , 1 October 2026
Hankook Tires WRC Finale as Toyota Clinches Sixth Straight Title

Alghero – October 01, 2026 -- Hankook Tire & Technology, the exclusive tire supplier to the FIA World Rally Championship, will equip all competitors at Rally Italia Sardegna, the season-closing round running October 1-4 around Alghero on Italy's Sardinia island.

By Editor , 1 October 2026
Aviation Giants Form Coalition to Shape EU Biometric Travel Rules

Courbevoie – October 01, 2026 -- ACI EUROPE, Amadeus, IATA, IDEMIA Public Security and SITA have formed the Responsible Biometrics Travel Industry Coalition, pressing EU policymakers to prevent the bloc's Digital Omnibus legislation from restricting voluntary biometric use in air travel.

The five organizations argue the current legislative proposal, designed to simplify Europe's digital rulebook and strengthen competitiveness, could unintentionally curb passengers' ability to opt into biometric verification at airports.

By Editor , 1 October 2026
Fresenius Takes Full Ownership of mAbxience in Biosimilars Push

Madrid – October 01, 2026 -- Fresenius SE & Co. KGaA has completed the acquisition of the remaining 45% stake in mAbxience from Insud Pharma, giving the German healthcare group full ownership of the Spanish biosimilars manufacturer.

By Editor , 30 September 2026
Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

By Editor , 30 September 2026
Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

By Editor , 30 September 2026
SUANNUTRA Localizes Lemon Verbena Supply Chain in Valencia, Spain

Madrid – September 30, 2026 -- SUANNUTRA SA has relocated cultivation of lemon verbena, a key botanical input for its branded ingredients, from South America to farms in Valencia, Spain, aiming to secure a more resilient and traceable supply chain.

By Editor , 30 September 2026
Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.